ResMed Inc.(RMD)Earnings, Financials & Key Ratios

RMD•NYSE

$209.64

$30.54B mkt cap·22.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryPatient monitoring and respiratory care

AboutResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.Show more

Revenue$5.15B+9.8%
EBITDA$1.92B+25.1%
Net Income$1.4B+37.2%
EPS (Diluted)9.51+37.4%
Gross Margin59.36%+4.7%
EBITDA Margin37.33%+13.9%
Operating Margin32.75%+16.3%
Net Margin27.22%+24.9%
ROE25.86%+13.9%
ROIC22.75%+26.2%
Debt/Equity0.14-20.6%
Interest Coverage133.05+364.0%

Analysis→Technical→

RMD Key Insights

ResMed Inc. (RMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 24.2%
✓Strong 5Y profit CAGR of 17.6%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 32.3% free cash flow margin
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak momentum: RS Rating 19 (bottom 19%)

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

RMD Price & Volume

ResMed Inc. (RMD) stock price & volume — 10-year historical chart

Loading chart...

RMD Growth Metrics

ResMed Inc. (RMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.85%

5 Years11.72%

3 Years12.88%

TTM10.28%

Profit CAGR

10 Years14.78%

5 Years17.64%

3 Years21.58%

TTM15.71%

EPS CAGR

10 Years14.43%

5 Years17.37%

3 Years21.52%

TTM16.05%

Return on Capital

10 Years21.04%

5 Years23.41%

3 Years23.18%

Last Year25.7%

RMD Recent Earnings

ResMed Inc. (RMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

Apr 30, 2026

EPS

$2.86

Est $2.79

+2.5%

Revenue

$1.4B

Est $1.4B

+0.8%

Q1 2026

Jan 29, 2026

EPS

$2.81

Est $2.74

+2.6%

Revenue

$1.4B

Est $1.4B

+1.6%

Q4 2025

Oct 30, 2025

EPS

$2.55

Est $2.51

+1.6%

Revenue

$1.3B

Est $1.3B

+0.2%

Q3 2025

Jul 31, 2025

EPS

$2.55

Est $2.55

+0.0%

Revenue

$1.3B

Est $1.3B

+0.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$2.86vs $2.79+2.5%	$1.4Bvs $1.4B+0.8%
Q1 2026	Jan 29, 2026	$2.81vs $2.74+2.6%	$1.4Bvs $1.4B+1.6%
Q4 2025	Oct 30, 2025	$2.55vs $2.51+1.6%	$1.3Bvs $1.3B+0.2%
Q3 2025	Jul 31, 2025	$2.55vs $2.55+0.0%	$1.3Bvs $1.3B+0.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
PHGKoninklijke Philips N.V.Direct Competitor	25.9B	27.23	24.95	-1.04%	5.02%	8.19%	0.74
ITGRInteger Holdings CorporationDirect Competitor	2.97B	86.29	29.86	7.57%	7.67%	8.23%	0.80
NVCRNovoCure LimitedDirect Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
INSPInspire Medical Systems, Inc.Direct Competitor	1.32B	45.70	9.35	13.6%	14.33%	17.98%	0.04
TNDMTandem Diabetes Care, Inc.Direct Competitor	1.24B	18.03	-5.93	7.93%	-20.17%	-141.98%	2.86
MDTMedtronic plcProduct Competitor	99.48B	77.60	21.50	3.62%	13%	9.45%	0.59
SYKStryker CorporationProduct Competitor	111.96B	292.33	34.80	11.16%	12.92%	15.04%	0.66
BSXBoston Scientific CorporationProduct Competitor	83.23B	56.00	28.87	19.87%	14.4%	12.4%	0.51

Compare RMD vs Peers

ResMed Inc. (RMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PHG

Most directly comparable listed peer for RMD.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare RMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs PHG, ITGR, NVCR, INSP

RMD Income Statement

ResMed Inc. (RMD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Sales/Revenue	2.07B	2.34B	2.61B	2.96B	3.2B	3.58B	4.22B	4.69B	5.15B	5.54B
Revenue Growth %	12.4%	13.23%	11.38%	13.44%	8.11%	11.93%	18.02%	10.95%	9.84%	10.28%
Cost of Goods Sold	864.99M	978.03M	1.07B	1.24B	1.36B	1.55B	1.87B	2.03B	2.09B	2.12B
COGS % of Revenue	41.85%	41.79%	41.05%	41.91%	42.47%	43.43%	44.22%	43.33%	40.64%	-
Gross Profit	1.2B▲ 0%	1.36B▲ 13.3%	1.54B▲ 12.8%	1.72B▲ 11.8%	1.84B▲ 7.1%	2.02B▲ 10.1%	2.36B▲ 16.4%	2.66B▲ 12.7%	3.05B▲ 15.1%	3.42B▲ 0%
Gross Margin %	58.15%	58.21%	58.95%	58.09%	57.53%	56.57%	55.78%	56.67%	59.36%	61.69%
Gross Profit Growth %	12.68%	13.35%	12.8%	11.79%	7.06%	10.07%	16.37%	12.72%	15.05%	-
Operating Expenses	775.95M	820.33M	957.32M	908.73M	935.42M	1.02B	1.22B	1.34B	1.37B	1.52B
OpEx % of Revenue	37.54%	35.05%	36.73%	30.73%	29.26%	28.62%	28.98%	28.5%	26.61%	-
Selling, General & Admin	553.97M	600.37M	645.01M	676.69M	670.39M	739.37M	874M	917.14M	991.02M	1.08B
SG&A % of Revenue	26.8%	25.65%	24.75%	22.88%	20.97%	20.66%	20.7%	19.57%	19.26%	-
Research & Development	144.47M	155.15M	180.65M	201.95M	225.28M	253.57M	287.64M	307.52M	331.28M	359M
R&D % of Revenue	6.99%	6.63%	6.93%	6.83%	7.05%	7.09%	6.81%	6.56%	6.44%	-
Other Operating Expenses	77.51M	64.81M	131.66M	30.09M	39.75M	31.08M	62.15M	110.75M	47.3M	4M
Operating Income	425.8M▲ 0%	541.83M▲ 27.3%	579.26M▲ 6.9%	809.66M▲ 39.8%	903.68M▲ 11.6%	1B▲ 10.7%	1.13B▲ 13.2%	1.32B▲ 16.6%	1.69B▲ 27.7%	1.9B▲ 0%
Operating Margin %	20.6%	23.15%	22.22%	27.38%	28.27%	27.96%	26.8%	28.17%	32.75%	34.28%
Operating Income Growth %	-0.74%	27.25%	6.91%	39.77%	11.61%	10.69%	13.15%	16.61%	27.69%	-
EBITDA	537.96M	661.79M	730.06M	991.03M	1.1B	1.19B	1.33B	1.54B	1.92B	2.08B
EBITDA Margin %	26.03%	28.28%	28.01%	33.51%	34.26%	33.37%	31.46%	32.79%	37.33%	37.61%
EBITDA Growth %	4.3%	23.02%	10.32%	35.75%	10.51%	9.03%	11.24%	15.64%	25.07%	13.92%
D&A (Non-Cash Add-back)	112.16M	119.96M	150.79M	181.37M	191.52M	193.84M	196.52M	216.21M	235.81M	184.32M
EBIT	456.73M	560.26M	555M	809.06M	912.35M	982.79M	1.16B	1.31B	1.68B	1.92B
Net Interest Income	-11.15M	-11.98M	-33.86M	-39.36M	-23.63M	-22.31M	-47.38M	-45.71M	-12.61M	-23.27M
Interest Income	17.09M	16.38M	2.3M	1.02M	362K	0	0	0	0	5.76M
Interest Expense	28.24M	28.36M	36.16M	40.38M	23.99M	22.31M	47.38M	45.71M	12.61M	29.03M
Other Income/Expense	-7.05M	-20.52M	-60.42M	-76.57M	-20.02M	-39.8M	-30.21M	-55.09M	-7.8M	4.82M
Pretax Income	418.74M▲ 0%	521.31M▲ 24.5%	518.85M▼ 0.5%	733.09M▲ 41.3%	883.66M▲ 20.5%	960.48M▲ 8.7%	1.1B▲ 14.7%	1.26B▲ 14.8%	1.68B▲ 32.6%	1.9B▲ 0%
Pretax Margin %	20.26%	22.28%	19.91%	24.79%	27.64%	26.84%	26.09%	27%	32.6%	34.37%
Income Tax	76.46M	205.72M	114.25M	111.41M	409.16M	181.05M	204.11M	243.85M	276.84M	383.74M
Effective Tax Rate %	18.26%	39.46%	22.02%	15.2%	46.3%	18.85%	18.53%	19.28%	16.5%	20.16%
Net Income	342.28M▲ 0%	315.59M▼ 7.8%	404.59M▲ 28.2%	621.67M▲ 53.7%	474.5M▼ 23.7%	779.44M▲ 64.3%	897.56M▲ 15.2%	1.02B▲ 13.7%	1.4B▲ 37.2%	1.52B▲ 0%
Net Margin %	16.56%	13.49%	15.52%	21.02%	14.84%	21.78%	21.25%	21.79%	27.22%	27.44%
Net Income Growth %	-2.87%	-7.8%	28.2%	53.65%	-23.67%	64.26%	15.15%	13.75%	37.2%	15.71%
Net Income (Continuing)	342.28M	315.59M	404.59M	621.67M	474.5M	779.44M	897.56M	1.02B	1.4B	1.52B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	2.40▲ 0%	2.19▼ 8.8%	2.80▲ 27.9%	4.27▲ 52.5%	3.24▼ 24.1%	5.30▲ 63.6%	6.09▲ 14.9%	6.92▲ 13.6%	9.51▲ 37.4%	10.33▲ 0%
EPS Growth %	-3.61%	-8.75%	27.85%	52.5%	-24.12%	63.58%	14.91%	13.63%	37.43%	16.05%
EPS (Basic)	2.42	2.21	2.83	4.31	3.27	5.34	6.12	6.94	9.55	-
Diluted Shares Outstanding	142.45M	143.99M	144.48M	145.65M	146.45M	147.04M	147.46M	147.55M	147.34M	147.04M
Basic Shares Outstanding	141.36M	142.76M	143.11M	144.34M	145.31M	146.07M	146.76M	147.02M	146.72M	146.47M
Dividend Payout Ratio	54.44%	63.21%	52.33%	36.21%	47.78%	31.48%	28.78%	27.65%	22.19%	-

RMD Balance Sheet

ResMed Inc. (RMD) balance sheet — assets, liabilities & shareholders' equity

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Total Current Assets	1.64B	1.07B	1.15B	1.52B	1.57B	1.93B	2.37B	2.36B	3.51B	4.06B
Cash & Short-Term Investments	821.93M	188.7M	147.13M	463.16M	295.28M	273.71M	227.89M	238.36M	1.21B	1.66B
Cash Only	821.93M	188.7M	147.13M	463.16M	295.28M	273.71M	227.89M	238.36M	1.21B	1.66B
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	450.53M	483.68M	528.48M	474.64M	614.29M	575.95M	704.91M	837.27M	990.67M	998.84M
Days Sales Outstanding	79.57	75.44	74	58.59	70.14	58.75	60.93	65.23	70.26	64.82
Inventory	268.32M	268.7M	349.64M	416.92M	457.03M	743.91M	998.01M	822.25M	927.71M	911.88M
Days Inventory Outstanding	113.22	100.28	119.27	122.8	122.87	174.75	195.08	147.84	161.91	159.48
Other Current Assets	0	0	0	75.26M	0	131.26M	179.93M	180.01M	164.5M	492.84M
Total Non-Current Assets	1.82B	2B	2.96B	3.06B	3.15B	3.16B	4.38B	4.51B	4.67B	4.72B
Property, Plant & Equipment	394.24M	386.55M	387.46M	535.68M	592.07M	630.5M	665.81M	699.15M	718.29M	728.57M
Fixed Asset Turnover	5.24x	6.05x	6.73x	5.52x	5.40x	5.68x	6.34x	6.70x	7.16x	7.63x
Goodwill	1.06B	1.07B	1.86B	1.89B	1.93B	1.94B	2.77B	2.84B	3.05B	3.47B
Intangible Assets	261.8M	215.18M	521.95M	448.17M	392.58M	345.94M	552.34M	485.9M	464.86M	0
Long-Term Investments	38.32M	41.23M	56.7M	51.1M	75.45M	67.22M	156.89M	169.77M	85.03M	408.08M
Other Non-Current Assets	3.74M	232.48M	94.28M	97.58M	85.46M	104.53M	105.56M	114.23M	100.81M	161.48M
Total Assets	3.47B▲ 0%	3.06B▼ 11.7%	4.11B▲ 34.1%	4.59B▲ 11.7%	4.73B▲ 3.1%	5.1B▲ 7.8%	6.75B▲ 32.5%	6.87B▲ 1.8%	8.17B▲ 18.9%	8.78B▲ 0%
Asset Turnover	0.60x	0.76x	0.63x	0.64x	0.68x	0.70x	0.63x	0.68x	0.63x	0.66x
Asset Growth %	6.43%	-11.66%	34.07%	11.68%	3.07%	7.78%	32.49%	1.79%	18.95%	69.14%
Total Current Liabilities	360.13M	511.25M	555.99M	602.76M	911.77M	689.3M	758.53M	910.65M	1.02B	1.35B
Accounts Payable	92.76M	92.72M	115.72M	135.79M	138.01M	159.25M	150.76M	237.73M	278.16M	273.3M
Days Payables Outstanding	39.14	34.6	39.48	39.99	37.1	37.41	29.47	42.74	48.55	45.97
Short-Term Debt	0	11.47M	11.99M	11.99M	12M	9.92M	9.9M	9.9M	9.9M	289.16M
Deferred Revenue (Current)	51.92M	60.83M	88.67M	98.62M	109.61M	108.67M	138.07M	152.55M	166.03M	689.13M
Other Current Liabilities	460K	2.37M	244K	0	0	1.95M	9.56M	4.65M	2.69M	609.47M
Current Ratio	4.57x	2.08x	2.06x	2.53x	1.73x	2.80x	3.12x	2.59x	3.44x	3.44x
Quick Ratio	3.82x	1.56x	1.43x	1.84x	1.23x	1.72x	1.81x	1.69x	2.53x	2.53x
Cash Conversion Cycle	153.65	141.11	153.8	141.39	155.9	196.09	226.54	170.33	183.63	178.33
Total Non-Current Liabilities	1.15B	493.69M	1.48B	1.49B	930.68M	1.05B	1.86B	1.1B	1.19B	941.16M
Long-Term Debt	1.08B	269.99M	1.26B	1.16B	643.35M	765.33M	1.43B	697.31M	658.39M	554.01M
Capital Lease Obligations	0	0	0	101.88M	114.78M	120.45M	116.85M	141.44M	153.01M	454.96M
Deferred Tax Liabilities	13.82M	13.08M	11.38M	13.01M	11.32M	9.71M	90.65M	79.34M	77.68M	311.18M
Other Non-Current Liabilities	2.43M	139.03M	128.11M	121.26M	69.73M	54.86M	105.35M	42.26M	141.52M	573.33M
Total Liabilities	1.51B	1B	2.04B	2.09B	1.84B	1.74B	2.62B	2.01B	2.21B	2.29B
Total Debt	1.08B	281.45M	1.27B	1.3B	793.72M	917.55M	1.58B	873.93M	851.81M	843.17M
Net Debt	256.68M	92.75M	1.12B	836.11M	498.44M	643.84M	1.35B	635.57M	-357.64M	-817.34M
Debt / Equity	0.55x	0.14x	0.61x	0.52x	0.28x	0.27x	0.38x	0.18x	0.14x	0.14x
Debt / EBITDA	2.01x	0.43x	1.74x	1.31x	0.72x	0.77x	1.19x	0.57x	0.44x	0.40x
Net Debt / EBITDA	0.48x	0.14x	1.54x	0.84x	0.46x	0.54x	1.02x	0.41x	-0.19x	-0.19x
Interest Coverage	16.18x	19.76x	15.35x	20.04x	38.03x	44.05x	24.53x	28.67x	133.05x	66.06x
Total Equity	1.96B▲ 0%	2.06B▲ 5.0%	2.07B▲ 0.6%	2.5B▲ 20.5%	2.89B▲ 15.6%	3.36B▲ 16.5%	4.13B▲ 22.9%	4.86B▲ 17.8%	5.97B▲ 22.7%	6.49B▲ 0%
Equity Growth %	15.66%	5.04%	0.64%	20.5%	15.56%	16.46%	22.89%	17.78%	22.69%	77.9%
Book Value per Share	13.76	14.30	14.34	17.14	19.70	22.86	28.01	32.97	40.50	44.15
Total Shareholders' Equity	1.96B	2.06B	2.07B	2.5B	2.89B	3.36B	4.13B	4.86B	5.97B	6.49B
Common Stock	569K	571K	575K	580K	583K	586K	588K	588K	761K	763K
Retained Earnings	2.32B	2.43B	2.44B	2.83B	3.08B	3.61B	4.25B	4.99B	6.08B	6.96B
Treasury Stock	-1.55B	-1.6B	-1.62B	-1.62B	-1.62B	-1.62B	-1.62B	-1.77B	-2.07B	-2.58B
Accumulated OCI	-189.06M	-224.33M	-253.01M	-283.98M	-193.49M	-312.75M	-272.53M	-251.53M	-74.7M	-24.91M
Minority Interest	0	0	0	0	0	0	0	0	0	0

RMD Cash Flow Statement

ResMed Inc. (RMD) cash flow — operating, investing & free cash flow history

Line item	Jun'17	Jun'18	Jun'19	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	Jun'25	TTM
Cash from Operations	414.05M	505.03M	459.05M	802.25M	736.72M	351.15M	693.3M	1.4B	1.75B	1.75B
Operating CF Margin %	20.03%	21.58%	17.61%	27.13%	23.05%	9.81%	16.42%	29.91%	34.04%	-
Operating CF Growth %	-24.43%	21.97%	-9.1%	74.76%	-8.17%	-52.34%	97.44%	102.11%	25%	68.74%
Net Income	342.28M	315.59M	404.59M	621.67M	474.5M	779.44M	897.56M	1.02B	1.4B	1.52B
Depreciation & Amortization	112.16M	119.96M	150.79M	181.37M	191.52M	193.84M	197.56M	216.21M	235.81M	263.32M
Stock-Based Compensation	45.92M	48.41M	52.07M	57.56M	63.93M	65.26M	71.14M	80.18M	91.66M	101.64M
Deferred Taxes	1.96M	11.59M	28.93M	39.58M	-3.31M	0	216K	0	0	0
Other Non-Cash Items	1.62M	411K	-286K	-7K	8.67M	20.69M	-11.05M	39.13M	6.66M	-4.23M
Working Capital Changes	-89.88M	9.06M	-177.05M	-97.92M	1.41M	-708.08M	-462.13M	44.78M	16.74M	9.67M
Change in Receivables	-63.6M	-32.36M	-18.01M	54.38M	-129.19M	19.35M	-106.51M	-134.28M	-76.68M	-64.78M
Change in Inventory	-41.6M	1.49M	-84.19M	-69.88M	-21.95M	-311.68M	-248.83M	172.2M	-80.17M	-8.19M
Change in Payables	34.58M	200.65M	-27.28M	-23.42M	210.71M	-247.63M	31.34M	0	90.96M	0
Cash from Investing	-81.89M	-101.82M	-1.08B	-179.86M	-158.46M	-229.92M	-1.16B	-269.78M	-200.04M	-295.26M
Capital Expenditures	-71.48M	-71.46M	-77.34M	-105.94M	-116.83M	-156.04M	-134M	-99.46M	-89.86M	-138.94M
CapEx % of Revenue	3.46%	3.05%	2.97%	3.58%	3.65%	4.36%	3.17%	2.12%	1.75%	-
Acquisitions	-7.27M	-902K	-951.38M	-27.91M	-39.07M	-42.78M	-1.01B	-133.46M	-139.25M	-163.98M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3.32M	8.97M	-8.63M	-10.61M	19.22M	-17.18M	15.2M	-15.4M	35.48M	35.96M
Cash from Financing	-262.87M	-1.03B	580.64M	-317.29M	-764.63M	-128.36M	422.87M	-1.12B	-606.25M	-907.75M
Debt Issued (Net)	-95M	-796.24M	807.49M	-94.01M	-522M	122M	665M	-730M	-40M	-10M
Equity Issued (Net)	38.32M	-69.19M	13.88M	48.18M	37.79M	47.38M	49.14M	-96.92M	-225.59M	-524.7M
Dividends Paid	-186.35M	-199.5M	-211.71M	-225.09M	-226.71M	-245.34M	-258.28M	-282.32M	-310.88M	-340.16M
Share Repurchases	0	-53.8M	-22.84M	0	0	0	0	-150.01M	-300.02M	-600.04M
Other Financing	-19.84M	38.23M	-29.01M	-46.36M	-53.71M	-52.41M	-32.99M	-10.05M	-29.79M	-32.89M
Net Change in Cash	90.5M▲ 0%	-633.23M▼ 799.7%	-41.57M▲ 93.4%	316.03M▲ 860.2%	-167.88M▼ 153.1%	-21.57M▲ 87.2%	-45.82M▼ 112.4%	10.47M▲ 122.9%	971.09M▲ 9175.0%	727.8M▲ 0%
Free Cash Flow	342.58M▲ 0%	433.57M▲ 26.6%	381.71M▼ 12.0%	696.32M▲ 82.4%	619.89M▼ 11.0%	195.11M▼ 68.5%	559.3M▲ 186.7%	1.29B▲ 130.0%	1.66B▲ 29.2%	1.75B▲ 0%
FCF Margin %	16.58%	18.53%	14.64%	23.55%	19.39%	5.45%	13.24%	27.46%	32.29%	31.68%
FCF Growth %	-28.65%	26.56%	-11.96%	82.42%	-10.98%	-68.53%	186.66%	130%	29.18%	12.14%
FCF per Share	2.40	3.01	2.64	4.78	4.23	1.33	3.79	8.72	11.28	11.28
FCF Conversion (FCF/Net Income)	1.21x	1.60x	1.13x	1.29x	1.55x	0.45x	0.77x	1.37x	1.25x	1.15x
Interest Paid	28.24M	28.36M	36.16M	40.38M	23.99M	22.31M	47.38M	45.71M	28.41M	13.76M
Taxes Paid	92.9M	170.65M	242.86M	180.36M	221.36M	478.12M	216.87M	278.4M	214.01M	-135.96M

RMD Key Ratios

ResMed Inc. (RMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	18.73%	15.7%	19.59%	27.21%	17.63%	24.96%	23.96%	22.7%	25.86%	24.41%
Return on Invested Capital (ROIC)	14.67%	18.6%	16.25%	18.6%	20.18%	20.31%	17.9%	18.03%	22.75%	22.75%
Gross Margin	58.15%	58.21%	58.95%	58.09%	57.53%	56.57%	55.78%	56.67%	59.36%	61.69%
Net Margin	16.56%	13.49%	15.52%	21.02%	14.84%	21.78%	21.25%	21.79%	27.22%	27.44%
Debt / Equity	0.55x	0.14x	0.61x	0.52x	0.28x	0.27x	0.38x	0.18x	0.14x	0.14x
Interest Coverage	16.18x	19.76x	15.35x	20.04x	38.03x	44.05x	24.53x	28.67x	133.05x	66.06x
FCF Conversion	1.21x	1.60x	1.13x	1.29x	1.55x	0.45x	0.77x	1.37x	1.25x	1.15x
Revenue Growth	12.4%	13.23%	11.38%	13.44%	8.11%	11.93%	18.02%	10.95%	9.84%	10.28%

RMD SEC Filings & Documents

ResMed Inc. (RMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Apr 30, 2026·SEC

Material company update

Jan 29, 2026·SEC

10-K Annual Reports

FY 2025

Aug 8, 2025·SEC

FY 2024

Aug 9, 2024·SEC

10-Q Quarterly Reports

FY 2026

Jan 30, 2026·SEC

FY 2025

Oct 31, 2025·SEC

FY 2025

Jan 31, 2025·SEC

RMD Frequently Asked Questions

ResMed Inc. (RMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

ResMed Inc. (RMD) reported $5.54B in revenue for fiscal year 2025. This represents a 15905% increase from $34.6M in 1996.

ResMed Inc. (RMD) grew revenue by 9.8% over the past year. This is steady growth.

Yes, ResMed Inc. (RMD) is profitable, generating $1.52B in net income for fiscal year 2025 (27.2% net margin).

Dividend & Returns

Yes, ResMed Inc. (RMD) pays a dividend with a yield of 1.01%. This makes it attractive for income-focused investors.

ResMed Inc. (RMD) has a return on equity (ROE) of 25.9%. This is excellent, indicating efficient use of shareholder capital.

ResMed Inc. (RMD) generated $1.75B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More RMD

ResMed Inc. (RMD) financial analysis — history, returns, DCA and operating performance tools

Full RMD Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

ResMed Inc.(RMD)Earnings, Financials & Key Ratios

RMD Key Insights

✓Strengths

✗Weaknesses

RMD Price & Volume

RMD Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

RMD Recent Earnings

RMD Peer Comparison

Compare RMD vs Peers

vs PHG

vs AMZN

Compare Top 5

RMD Income Statement

RMD Balance Sheet

RMD Cash Flow Statement

RMD Key Ratios

RMD SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

RMD Frequently Asked Questions

Explore More RMD

Full RMD Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation